Matrix metalloproteinase 9 is decreased in natalizumab-treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy

2017 ◽  
Vol 82 (2) ◽  
pp. 186-195 ◽  
Author(s):  
Nicolas Fissolo ◽  
Béatrice Pignolet ◽  
Clara Matute-Blanch ◽  
Juan Carlos Triviño ◽  
Berta Miró ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
At Risk ◽  
Matrix Metalloproteinase ◽  
Progressive Multifocal Leukoencephalopathy ◽  
Matrix Metalloproteinase 9 ◽  
Patients At Risk ◽  
Multiple Sclerosis Patients ◽  
Metalloproteinase 9

scholarly journals Immunological biomarkers identifying natalizumab-treated multiple sclerosis patients at risk of progressive multifocal leukoencephalopathy

2014 ◽  
Vol 277 (1-2) ◽  
pp. 6-12 ◽  
Author(s):  
Federico Serana ◽  
Marco Chiarini ◽  
Alessandra Sottini ◽  
Diego Bertoli ◽  
Viviana Giustini ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
At Risk ◽  
Progressive Multifocal Leukoencephalopathy ◽  
Patients At Risk ◽  
Multiple Sclerosis Patients

Matrix Metalloproteinase-7, Matrix Metalloproteinase-9, and Disease Activity in Pediatric Multiple Sclerosis

2013 ◽  
Vol 48 (3) ◽  
pp. 255-256
Author(s):  
Ünsal Yılmaz ◽  
Kıvılcım Gücüyener ◽  
Esra Gürkaş ◽  
Ercan Demir ◽  
Ayşe Serdaroğlu ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Matrix Metalloproteinase ◽  
Disease Activity ◽  
Matrix Metalloproteinase 9 ◽  
Pediatric Multiple Sclerosis ◽  
Matrix Metalloproteinase 7 ◽  
Metalloproteinase 9
Sign in / Sign up

Export Citation Format

Share Document